Corcept Therapeutics INC Form 4 insider transactions

Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 296 shares of common stock on September 16, 2026 for $100.82 per share.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 17, 2026.

Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, sold 10,000 shares of common stock on September 14, 2026.

James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on September 15, 2026.

William Guyer, Chief Development Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.

Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 25,000 shares of common stock on September 1, 2026.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.

Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 58,333 shares of common stock on September 1, 2026.

Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.

David L Mahoney, a Director of Corcept Therapeutics Inc, sold 103,606 shares of common stock on August 18, 2026.

Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 3,664 shares of common stock on August 14, 2026 for $114.49 per share.

James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on August 14, 2026.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, sold 10,000 shares of common stock on August 17, 2026 for $116.26 per share.

Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 1,031 shares of common stock on August 10, 2026 for $114.52 per share.

William Guyer, Chief Development Officer of Corcept Therapeutics Inc, sold 16,300 shares of common stock on August 10, 2026.

William Guyer, Chief Development Officer of Corcept Therapeutics Inc, sold 3,700 shares of common stock on August 4, 2026 for $113.12 per share.

Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 20,305 shares of common stock on August 3, 2026 for $114.70 per share.

Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, sold 1,540 shares of common stock on August 3, 2026 for $114.16 per share.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 80,000 shares of common stock on July 30, 2026.

James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on July 15, 2026.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 40,000 shares of common stock on July 15, 2026.

Gary Charles Robb, Chief Business Officer at Corcept Therapeutics Inc., reported a transaction involving common stock on May 27, 2026.

Corcept Therapeutics Chief Development Officer William Guyer reported transactions involving company stock, including the acquisition of stock options and the sale of common stock.

Sean Maduck, President of Corcept Endocrinology, engaged in significant stock transactions, including acquisitions and sales, on July 1, 2026, under a Rule 10b5-1 plan.

Corcept Therapeutics Director James N. Wilson reported the sale of Corcept Therapeutics Inc. common stock valued at over $1 million, executed under a pre-established 10b5-1 trading plan.

Corcept Therapeutics Director David L. Mahoney reported a sale of 20,000 shares of common stock on June 17, 2026, for an aggregate price of $1,690,500.

Corcept Therapeutics Chief Financial Officer, Atabak Mokari, reported a series of stock transactions on June 15, 2026, including the acquisition of stock options and the sale of common stock.

Chief Development Officer William Guyer exercised options and sold 20,000 shares of Corcept Therapeutics common stock.

Chief Accounting & Technology Officer Joseph Douglas Lyon reported stock acquisitions and tax-related withholdings.